Dendrite Announces Grants under New Hire Authorization.

BEDMINSTER, N.J. -- Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), as amended October 14, 2003, Dendrite International, Inc. (NASDAQ: DRTE) today announced that stock options covering an aggregate of 500,000 shares of common stock and units representing an aggregate of 250,000 restricted shares of common stock were granted to Joseph Ripp on November 1, 2005 in connection with his appointment as the President and Chief Operating Officer of the Company. The Company also announced that stock options covering 140,000 shares were granted to 16 non-executive officer employees on October 17, 2005 and options covering 2,000 shares were granted to one non-executive officer employee on July 19, 2005, all as an inducement to entering into employment with the Company.

All such option and restricted stock unit grants were made under the Company's New Hire Authorization. All options granted include a ten year duration and an exercise price equal to the closing price of Dendrite's stock on the business day immediately preceding the date of grant. All options vest on December 31, 2005, but the right to sell the shares underlying the options accrues in three equal installments on each of the first three anniversaries of the date of grant. The restricted stock units vest in three equal installments on each of the first three anniversaries of the date of grant.

About Dendrite

Founded in 1986, Dendrite International, Inc., (NASDAQ: DRTE) provides diversified sales, marketing, clinical and compliance solutions to the global life sciences and pharmaceutical industry. With clients in more than 50 countries, including the world's top 20 pharmaceutical companies, Dendrite strives to be the first source for expert promotional and sales effectiveness solutions. For more information, please visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This document contains forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for our products; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; risks associated with foreign currency fluctuations as they affect our non-U.S. operations; increased competition; risks associated with our expanded international operations and our ability to adopt and respond successfully to the unique risks involved in our non-U.S. operations; risks associated with acquisitions; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships or acquisitions; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the Company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The Company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in expectations or assumptions or other changes affecting such forward-looking statements, even if such results or changes make it clear that any such projected results will not be achieved.